Takeda and Orexigen Announce FDA Approval of Contrave Extended-Release Tablets for Chronic Weight Management
![](/46/pdcnewsitem/03/36/58/upsymqFRfnTPzGd.png)
Takeda Pharmaceutical Company Ltd, its wholly-owned subsidiary Takeda Pharmaceuticals USA, Inc. and Orexigen Therapeutics, Inc. have jointly announced that FDA has approved Contrave (naltrexone HCI and bupropion HCI) extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.
“Some individuals seeking to manage their weight may require a treatment plan that includes more than
lifestyle modification with diet and exercise,” said Dr Ken Fujioka, Director, Center for Weight Management,
Division of Diabetes and Endocrinology at Scripps Clinic. “Clinical trial data for Contrave demonstrates that
this new treatment, when used as an adjunct to a reduced-calorie diet and increased physical activity, is a
therapeutic option for some adults who are either overweight with a comorbidity, or obese. In my clinic I
often treat patients who fit these criteria, and now, with the approval of Contrave, I am excited to have a new
treatment option to consider for my patients.”
“The FDA approval of Contrave is a significant milestone in Takeda's and Orexigen’s commitment to
leading innovation in medicine for patients and physicians dealing with chronic conditions and diseases,
such as obesity,” said Douglas Cole, President, Takeda Pharmaceuticals USA, Inc. “It’s important that
physicians and appropriate patients have options when discussing weight management, especially when
you look at the prevalence of obesity in today’s society. We’re excited about the addition of Contrave to
our Cardiovascular and Metabolic Disease Portfolio.”
Contrave is an important addition to Takeda’s portfolio of cardiometabolic products. Takeda is committed
to providing patients with obesity with treatment options that help address their needs, and the company is
planning to commercially launch Contrave in the fall of 2014.
Related News
-
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance